Avastin®
Bevacizumab is a recombinant humanized monoclonal antibody targeting VEGF-A. It inhibits angiogenesis and is used across multiple tumor types.
| Dosage Form | IV Injectable (Solution) |
| Strength | 25 mg/mL; 100 mg, 400 mg vials |
| Storage | Store at 2–8°C. Do not freeze or shake. |
| Category | Oncology |
| Availability | Available for Transfer |
Metastatic colorectal cancer; NSCLC; renal cell carcinoma; glioblastoma; cervical cancer; ovarian cancer; hepatocellular carcinoma.
Binds to vascular endothelial growth factor A (VEGF-A), preventing its interaction with VEGFR-1 and VEGFR-2 receptors, thereby inhibiting tumor angiogenesis.
Each Burrard Pharmaceuticals technology transfer package for Bevacizumab includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.